ASH 2024 | A Phase I study of CPX-351 plus gilteritinib in R/R FLT3-mutated AML
David Sallman, MD, Moffitt Cancer Center, Tampa, FL, briefly comments on a Phase I study (NCT05024552) investigating a treatment regimen of CPX-351 plus gilteritinib in relapsed/refractory (R/R) FLT3-mutated acute myeloid leukemia (AML), highlighting the potential of combination therapy to improve response rates and tolerability, but notes that this combination may not be synergistic and is unlikely to be a pivotal strategy. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (AI-generated)
So I think we’re all excited about different combination therapy. We clearly know targeted inhibitors work, but monotherapy responses with gilteritinib or others have been underwhelming. You know, you’re talking short durations of remission, relatively low response rates, you know, less than half of patients getting a good response. So really building upon earlier data that CPX had actually quite strong activity in FLT3-mutant patients, basically just combining maybe a better chemo backbone with gilteritinib...
So I think we’re all excited about different combination therapy. We clearly know targeted inhibitors work, but monotherapy responses with gilteritinib or others have been underwhelming. You know, you’re talking short durations of remission, relatively low response rates, you know, less than half of patients getting a good response. So really building upon earlier data that CPX had actually quite strong activity in FLT3-mutant patients, basically just combining maybe a better chemo backbone with gilteritinib. We clearly see responses in that setting. I think in general, whether or not the combination is truly synergistic, I don’t think necessarily it is. And so how much the combination is worth it or not. We could say that it’s quite well-tolerated. It’s easy enough to do. I think it’s an option as far as if you’re giving, let’s say, salvage chemotherapy and you’re adding in your FLT3 inhibitor. But I don’t think it’s remarkable enough that, hey, we should then think about a pivotal strategy from that perspective.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Abbvie: Consultancy; Agios: Consultancy; Axiom: Consultancy; Gilead: Consultancy; Celyad: Consultancy; Froghorn: Consultancy; Incyte: Consultancy; Intellisphere, LLC: Consultancy; Johnson & Johnson: Consultancy; Kite: Consultancy, Membership on an entity’s Board of Directors or advisory committees; Magenta Therapeutics: Consultancy, Membership on an entity’s Board of Directors or advisory committees; NextTech: Consultancy; Novartis: Consultancy, Membership on an entity’s Board of Directors or advisory committees; AvenCell: Membership on an entity’s Board of Directors or advisory committees; Astellas: Membership on an entity’s Board of Directors or advisory committees; BlueBird Bio: Membership on an entity’s Board of Directors or advisory committees; BMS: Membership on an entity’s Board of Directors or advisory committees; Dark Blue Therapeutics: Membership on an entity’s Board of Directors or advisory committees; Intellia: Membership on an entity’s Board of Directors or advisory committees; Jasper Therapeutics: Membership on an entity’s Board of Directors or advisory committees; NKARTA: Membership on an entity’s Board of Directors or advisory committees; Orbital Therapeutics: Membership on an entity’s Board of Directors or advisory committees; Rigel Pharmaceuticals: Membership on an entity’s Board of Directors or advisory committees; Shattuck Labs: Membership on an entity’s Board of Directors or advisory committees; Servier: Membership on an entity’s Board of Directors or advisory committees; Syndax: Membership on an entity’s Board of Directors or advisory committees; Syros: Membership on an entity’s Board of Directors or advisory committees; Apera: Research Funding; Jazz: Research Funding.
